Skip to main content
John Mascola, MD, Infectious Disease, Rockville, MD

JohnRobertMascolaMD

Infectious Disease • Rockville, MD

HIV/AIDS Medicine, Microbiology

Physician

Join to view full profile

Dr. Mascola is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Mascola's full profile

Already have an account?

  • Office

    Rockville
    Rockville, MD 20853

Education & Training

  • Naval Medical Center (San Diego)
    Naval Medical Center (San Diego)Residency, Internal Medicine, 1987 - 1989
  • Naval Medical Center (San Diego)
    Naval Medical Center (San Diego)Internship, Internal Medicine, 1985 - 1986
  • Georgetown University School of Medicine
    Georgetown University School of MedicineClass of 1985

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1987 - 2022

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 2002

Publications & Presentations

PubMed

Journal Articles

  • Evaluation of the mRNA-1273 Vaccine Against SARS-CoV-2 in Nonhuman Primates  
    John R Mascola, The New England Journal of Medicine
  • Monoclonal Antibodies for Prevention and Treatment of COVID-19  
    John R Mascola, Myron S Cohen, JAMA
  • Structure-Based Design of a Quadrivalent Fusion Glycoprotein Vaccine for Human Parainfluenza Virus Types 1–4  
    John Mascola, MD, Proceedings of the National Academy of Sciences
  • Join now to see all

Authored Content

  • Epitope-Based Vaccine Design Yields Fusion Peptide-Directed Antibodies That Neutralize Diverse Strains of HIV-1June 2020

Press Mentions

  • NIAID Vaccine R&D Director Who Collaborated with Moderna on COVID-19 Vaccine to Retire
    NIAID Vaccine R&D Director Who Collaborated with Moderna on COVID-19 Vaccine to RetireFebruary 16th, 2022
  • Vaccine Makers Pursue Omicron-Targeted Shots That Health Officials Say Might Not Be Needed
    Vaccine Makers Pursue Omicron-Targeted Shots That Health Officials Say Might Not Be NeededJanuary 14th, 2022
  • Covid-19 Vaccine Makers Assess Omicron Response
    Covid-19 Vaccine Makers Assess Omicron ResponseNovember 29th, 2021
  • Join now to see all

Grant Support

  • Isolation And Deep Sequencing Of Monoclonal Antiobodies Against HIVNational Institute Of Allergy And Infectious Diseases2011
  • Determination Of The Neutralization Specificity In Broadly Neutralizing HIV SERANational Institute Of Allergy And Infectious Diseases2010–2011
  • Preclinical Evaluation Of Neutralizing Antibodies Elicited By HIV-1 ImmunogensNational Institute Of Allergy And Infectious Diseases2009–2011
  • Non-Human Primate Immunogenicity Studies Of HIV-1 ImmunogensNational Institute Of Allergy And Infectious Diseases2009–2011
  • NON Human Primate Models Of SIV And HIV Immune ProtectionNational Institute Of Allergy And Infectious Diseases2009–2011
  • Measurement Of HIV Neutralization Using Quantitative AssaysNational Institute Of Allergy And Infectious Diseases2009–2011
  • Isolation Of Monoclonal Antiobodies Against HIVNational Institute Of Allergy And Infectious Diseases2009–2010
  • Evaluation Of Antibody Specificities In Broadly Neutralizing HIV SERANational Institute Of Allergy And Infectious Diseases2009
  • Measurement Of HIV Neutralization Using Quantitative AssaysNational Institute Of Allergy And Infectious Diseases2008
  • Isolation Of Monoclonal Antiobodies Against HIVNational Institute Of Allergy And Infectious Diseases2008
  • Evaluation Of Antibody Specificities In Broadly Neutralizing HIV SERANational Institute Of Allergy And Infectious Diseases2008
  • Preclinical Evaluation Of Neutralizing Antibodies Elicited By HIV-1 ImmunogensNational Institute Of Allergy And Infectious Diseases2007–2008
  • Non-Human Primate Immunogenicity Studies Of HIV-1 ImmunogensNational Institute Of Allergy And Infectious Diseases2007–2008
  • NON Human Primate Models Of SIV And HIV Immune ProtectionNational Institute Of Allergy And Infectious Diseases2007–2008
  • Measurement Of HIV Neutralization Using Flow Cytometric &Reporter Virus AssaysNational Institute Of Allergy And Infectious Diseases2007
  • Non-Human Primate Immunogenicity Studies Of HIV-1 ImmunoNational Institute Of Allergy And Infectious Diseases2005–2006
  • Measurement Of HIV Neutralization Using Flow CytometricNational Institute Of Allergy And Infectious Diseases2005–2006
  • Macaque Studies Of Correlates Of HIV ProtectionNational Institute Of Allergy And Infectious Diseases2004–2006
  • Preclinical Evaluation Of Neutralizing Antibodies ElicitNational Institute Of Allergy And Infectious Diseases2002–2006
  • Evaluation Of Neutralizing Antibodies Elicited By HIV-1National Institute Of Allergy And Infectious Diseases2005
  • Preclinical Evaluation Of HIV-1 Neutralizing AntibodiesNational Institute Of Allergy And Infectious Diseases2004
  • Measurement Of HIV NeutralizationNational Institute Of Allergy And Infectious Diseases2004
  • Immunogenicity Studies Of HIV-1 ImmunogensNational Institute Of Allergy And Infectious Diseases2004
  • Optimizing Measurement Of HIV-1 Neutralization Using ANational Institute Of Allergy And Infectious Diseases2003
  • Passive Antibody Protection In The Setting Of Active CELNational Institute Of Allergy And Infectious Diseases2002–2003
  • Non-Human Primate Immunogenicity Studies Of DNA Prime, RNational Institute Of Allergy And Infectious Diseases2002–2003
  • Optimizing Measurement Of HIV-1 Neutralization Using A FNational Institute Of Allergy And Infectious Diseases2002
  • Passive Antibody Protection In SHIV Challenge ModelNational Heart, Lung, And Blood Institute1997–1999

Dr. John Mascola, Dr. John Mascola, MD, Dr. J Mascola, Dr. John Robert Mascola